Browsing by Author "Arslan, Hande"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • No Thumbnail Available
    Publication
    Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results
    (Ankara Mikrobiyoloji Kulübü, 2018-10-01) Karataylı, Ersin; Soydemir, Ege; Aksoy, Zeynep Buşra; Kızılpınar, Mehtap; Altay Kocak, Aylin; Karataylı, Senem Ceren; Yurdcu, Esra; Yıldırım, Umut; Guriz, Haluk; Bozdayı, Gülendam; Yurdaydın, Cihan; İlhan, Osman; Yıldırım, Yasin; Bozdayı, A. Mithat; Oğuz, Acelya Yalçıntaş; Barış, Ahmet; Alp, Alpaslan; Aksözek, Alper; Sayıner, Arzu; Karagül, Aydan; Ordu, Aylin; İstanbullu, Aye; Otlu, Barış; Arıdoğan, Buket; Aksu, Burak; Buruk, C. Kurtuluş; Karahan, Ceren; Güney, Çakır; Toksöz, Devrim; Yıldırım, Dilara; Çolak, Dilek; Dağlar, Duygu Eren; Fındık, Duygu; Kas, Elif; Calışkan, Emel; Zeyrek, Fadile Yıldız; Arslan, Fatma; Demir, Feyza; Milletli, Fikriye; Kibar, Filiz; Özdinçer, Furkan; Dündar, Gülnür; Arslan, Hande; Ağça, Harun; Aliskan, Hikmet Eda; Güdücuoğlu, Hüseyin; Fidan, Işıl; Akyar, Isin; Afsar, Ilhan; Kaleli, İlknur; Dönmez, İsmail; YanIk, Kemalettin; Midilli, Kenan; çubukcu, Kivanc; Özdemir, Mehmet; Acar, Melek; Yalinay, Meltem; Kuşkucu, Mert Ahmet; Bakırcı, Mustafa Zahir; Aydın, Neriman; Yılmaz, Neziha; Çeken, Nihan; Ziyade, Nihan; Yılmaz, Nisel; Özgümüş, Osman Birol; Gitmişoğlu, Özlem; Demirgan, Recep; Kesli, Recep; Güçkan, Rıdvan; Sertoz, Ruchan; Akgün, Sadık; Aksaray, Sebahat; Tezcan, Seda; Kaygusuz, Sedat; Gökahmetoğlu, Selma; Meşe, Sevim; Bayik, Seyit Ahmet; Akcalı, Sinem; Gürcan, Saban; Karsligil, Tekin; Us, Tercan; Özekinci, Tuncer; Pilgir, Tulin; Aslan, Uğur; Dinc, Ugur; Coşkun, Umut Safiye Say; Çetinkol, Yeliz; Keskin, Yusuf; Ayaydın, Zeynep; Toraman, Zulal Asçı; MOTAKK HBV HCV Calisma Grubu; AĞCA, HARUN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı; 0000-0002-2651-2034; ISU-9626-2023
    MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load. The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.
  • No Thumbnail Available
    Publication
    Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results
    (Ankara Microbiology Soc, 2018-10-01) Karatayli, Ersin; Soydemir, Ege; Aksoy, Zeynep Busra; Kizilpinar, Mehtap; Altay Kocak, Aylin; Karatayli, Senem Ceren; Yurdcu, Esra; Yildirim, Umut; Guriz, Haluk; Bozdayi, Gulendam; Yurdaydin, Cihan; Ilhan, Osman; Yildirim, Yasin; Bozdayi, A. Mithat; Oguz, Acelya Yalcintas; Baris, Ahmet; Alp, Alpaslan; Aksozek, Alper; Sayiner, Arzu; Karagul, Aydan; Ordu, Aylin; Istanbullu, Aye; Otlu, Baris; Aridogan, Buket; Aksu, Burak; Buruk, C. Kurtulus; Karahan, Ceren; Guney, Cakir; Toksoz, Devrim; Yildirim, Dilara; Colak, Dilek; Daglar, Duygu Eren; Findik, Duygu; Kas, Elif; Caliskan, Emel; Zeyrek, Fadile Yildiz; Arslan, Fatma; Demir, Feyza; Milletli, Fikriye; Kibar, Filiz; Ozdincer, Furkan; Dundar, Gulnur; Arslan, Hande; Agca, Harun; Aliskan, Hikmet Eda; Guducuoglu, Huseyin; Fidan, Isil; Akyar, Isin; Afsar, Ilhan; Kaleli, Ilknur; Donmez, Ismail; Yanik, Kemalettin; Midilli, Kenan; Cubukcu, Kivanc; Ozdemir, Mehmet; Acar, Melek; Yalinay, Meltem; Kuskucu, Mert Ahmet; Bakici, Mustafa Zahir; Aydin, Neriman; Yilmaz, Neziha; Ceken, Nihan; Ziyade, Nihan; Yilmaz, Nisel; Ozgumus, Osman Birol; Gitmisoglu, Ozlem; Demirgan, Recep; Kesli, Recep; Guckan, Ridvan; Sertoz, Ruchan; Akgun, Sadik; Aksaray, Sebahat; Tezcan, Seda; Kaygusuz, Sedat; Gokahmetoglu, Selma; Mese, Sevim; Bayik, Seyit Ahmet; Akcali, Sinem; Gurcan, Saban; Karsligil, Tekin; Us, Tercan; Ozekinci, Tuncer; Pilgir, Tulin; Aslan, Ugur; Dinc, Ugur; Coskun, Umut Safiye Say; Cetinkol, Yeliz; Keskin, Yusuf; Ayaydin, Zeynep; Toraman, Zulal Asci; AĞCA, HARUN; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; 0000-0002-2651-2034; ISU-9626-2023
    MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load. The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.
  • No Thumbnail Available
    Item
    Mucormycosis in Turkey
    (Lippincott Williams & Wilkins, 2018-07) Demirkaya, Melike H.; Arslan, Hande; Alp, Sehnaz; Aypak, Adalet; Demiroğlu, Ziya; Ersöz, Gülden; Hasanoğlu, İmran; Kurtaran, Behice; Tekce, Yasemin Tezer; Tunccan, Özlem Güzel; Haberal, Mehmet; Kazak, Esra; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; AAG-8459-2021
  • Thumbnail Image
    Publication
    Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to extended-spectrum-beta-lactamase-producing enterobacterales in kidney transplant recipients
    (Amer Soc Microbiology, 2021-08-05) Gutierrez-Gutierrez, Belen; Perez-Nadales, Elena; Perez-Galera, Salvador; Fernandez-Ruiz, Mario; Carratala, Jordi; Oriol, Isabel; Cordero, Elisa; Antonio Lepe, Jose; Tan, Ban Hock; Corbella, Laura; Paul, Mical; Natera, Alejandra M.; David, Miruna D.; Montejo, Miguel; Iyer, Ranganathan N.; Pierrotti, Ligia Camera; Merino, Esperanza; Steinke, Seema Mehta; Rana, Meenakshi M.; Munoz, Patricia; Mularoni, Alessandra; van Delden, Christian; Grossi, Paolo Antonio; Seminari, Elena Maria; Günseren, Filiz; Lease, Erika D.; Roilides, Emmanuel; Fortun, Jesus; Arslan, Hande; Coussement, Julien; Tufan, Zeliha Kocak; Pilmis, Benoit; Rizzi, Marco; Loeches, Belen; Eriksson, Britt Marie; Abdala, Edson; Soldani, Fabio; Lowman, Warren; Clemente, Wanessa Trindade; Bodro, Marta; Carmen Farinas, Maria; Kazak, Esra; Martinez-Martinez, Luis; Maria Aguado, Jose; Torre-Cisneros, Julian; Pascual, Alvaro; Rodriguez-Bano, Jesus; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; AAG-8459-2021
    There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.
  • No Thumbnail Available
    Item
    Urinary tract infections after kidney transplantation in fourteen medical centers in Turkey
    (Lippincott Williams & Wilkins, 2018-07) Arslan, Hande; Demirkaya, Melike H.; Ak, Öznur; Aydın, Mehtap; Aydın, Güle; Aypak, Adalet; Bayındır, Yaşar; Demiroğlu, Ziya; Ergen, Pınar; Ersoz, Gulden; Gündeş, Sibel; Kurtaran, Behice; Oğuz, Vildan; Tekce, Yasemin Tezer; Haberal, Mehmet; Kazak, Esra; AAG-8459-2021